Chemotherapy News and Research

Latest Chemotherapy News and Research

OPKO Health signs agreement with Schering-Plough to acquire assets relating to NK-1 program

OPKO Health, Inc. today announced that it has entered into a definitive agreement with Schering-Plough Corporation to acquire assets relating to Schering’s neurokinin-1 (NK-1) receptor antagonist program. Rolapitant, the lead product, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.

14 Oct 2009

Older generation antibiotic for treating colon cancer

A new Tel Aviv University drug, based on an older generation antibiotic, may provide doctors with an effective and innovative method of treating colon cancer in both its incipient and full-blown stages ― and minimize the need for painful, uncomfortable colonoscopies and surgical polyp removal.

14 Oct 2009

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic.

14 Oct 2009

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

An anticancer drug that is commonly used to treat lung and colon malignancies is having a benefit and potentially prolonging survival in patients with invasive bladder cancer, researchers reported at the 2009 Clinical Congress of the American College of Surgeons.

14 Oct 2009

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.

14 Oct 2009

Statistical model helps identify patients who need to undergo further cancer treatment

A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy. The analysis, to be published in the December 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, concludes that the model, which considers both how far the cancer has spread and other information, such as how the cancer cells look under the microscope and the time between diagnosis and surgery, could better identify patients who need to undergo further treatment.

13 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Study on Lumalier's automated UV device for decontaminating hospital rooms presented at the ICAAC

In a study presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), researchers used a mobile, automated UV device to decontaminate hospital rooms at the Cleveland Veterans Affairs (VA) Medical Center in Ohio and analyzed its ability to remove troublesome bacteria, including C. difficile spores.

12 Oct 2009

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).

12 Oct 2009

First evidence that personalized medicine leads to better outcomes

A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy.

12 Oct 2009

Breast cancer patients who achieve pathological complete response have better outcomes

Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.

12 Oct 2009

M. D. Anderson Cancer Center researchers announce study results of treatment for rare pediatric brain cancer

A team of researchers led by The University of Texas M. D. Anderson Cancer Center unveiled results today from the largest-ever collaborative study addressing the treatment of a rare pediatric brain tumor. The findings suggest a new standard protocol could improve survival nearly two-fold for pediatric patients with choroid plexus tumors, as reported at the 41st Annual Meeting of the International Society of Pediatric Oncology (SIOP).

12 Oct 2009

New law lets injured or ill college students keep parents' health insurance

A new federal law took effect Friday, allowing seriously ill or injured college students to keep their parents' insurance for up to a year while they take time off from school.

12 Oct 2009

Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®.

12 Oct 2009

MedaSorb Technologies raises $1.3 million to help finance ongoing European Sepsis Trial

MedaSorb Technologies Corporation and its wholly-owned subsidiary CytoSorbents, Inc., announced that it has raised $1.3 million in the exercise of the warrant attached to the Series B financing completed in August 2008. Dr. Phillip Chan, Chief Executive Officer, stated, "We are pleased to have the continued support of our existing investors.

9 Oct 2009

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

Genomic Health, Inc. today announced results from a study demonstrating the critical role of manual microdissection to remove all biopsy cavities from breast cancer specimens. Genomic Health's Oncotype DX is the only commercially available breast cancer test that employs manual microdissection following review by a board certified surgical pathologist with breast expertise to predict a patient's benefit from chemotherapy and risk of disease recurrence.

9 Oct 2009

OncoGenex Pharmaceuticals president named Canada's Pacific Ernst & Young's Entrepreneur Of The Year

OncoGenex Pharmaceuticals, Inc., announced today that Scott Cormack, president and chief executive officer of OncoGenex, has been named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R). The Ernst & Young Entrepreneur Of The Year(R) Award is a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses.

9 Oct 2009

TargetEx to be the coordinator for CancerGrid consortium

TargetEx llc, Budapest announced today that the Research Directorate General of the Commission of the European Communities approved the transfer of the coordinator responsibilities of the European Cancer Research Consortium (CancerGrid) to TargetEx.

9 Oct 2009

Manchester scientists test radioimmunotherapy in early phase clinical trials

MANCHESTER SCIENTISTS are testing an emerging therapy called radioimmunotherapy (RIT) in early phase clinical trials, according to a presentation at the NCRI Cancer Conference in Birmingham today (Wednesday).

9 Oct 2009

Emisphere Technologies announces commercial launch of oral Eligen B12

Emisphere Technologies, Inc. today announced that the Company is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation.

8 Oct 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

OPKO Health signs agreement with Schering-Plough to acquire assets relating to NK-1 program

Older generation antibiotic for treating colon cancer

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

Statistical model helps identify patients who need to undergo further cancer treatment

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Study on Lumalier's automated UV device for decontaminating hospital rooms presented at the ICAAC

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

First evidence that personalized medicine leads to better outcomes

Breast cancer patients who achieve pathological complete response have better outcomes

M. D. Anderson Cancer Center researchers announce study results of treatment for rare pediatric brain cancer

New law lets injured or ill college students keep parents' health insurance

Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma

MedaSorb Technologies raises $1.3 million to help finance ongoing European Sepsis Trial

Manual microdissection to remove biopsy cavities from breast cancer specimens essential

OncoGenex Pharmaceuticals president named Canada's Pacific Ernst & Young's Entrepreneur Of The Year

TargetEx to be the coordinator for CancerGrid consortium

Manchester scientists test radioimmunotherapy in early phase clinical trials

Emisphere Technologies announces commercial launch of oral Eligen B12

Cancer Research - Second Edition eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Todd Bauman and Chris Povich

Newsletters you may be interested in